Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine
NCT00435812
Completed
The purpose of this study is to find out if a new investigational hepatitis B virus vaccine, HEPLISAV™, is safe and effective compared with Engerix-B® vaccine in subjects 11-55 years old. The primary hypothesis is that the seroprotective immune response of HEPLISAV™ is at least as good as that of Engerix-B®.
Gender:
ALL
Ages:
Between 11 years and 55 years
Trial Updated:
03/18/2019
Locations: Not set, Edmonton, Alberta +17 locations
Conditions: Hepatitis B
Register for Updates
Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine
NCT01005407
Completed
The purpose of the study is to evaluate the safety, immunogenicity and lot-to-lot consistency of an investigational hepatitis B virus vaccine, HEPLISAV™, in healthy adults 40 to 70 years of age
Gender:
ALL
Ages:
Between 40 years and 70 years
Trial Updated:
03/18/2019
Locations: Not set, Huntsville, Alabama +31 locations
Conditions: Healthy
Register for Updates
Immunogenicity and Safety of Gardasil-9 and Cervarix
NCT02567955
Completed
A ninevalent HPV vaccine (Gardasil-9) has been recently approved for clinical use. No data on immunogenicity and safety of interchangeable use of the ninevalent and the bivalent vaccine (Cervarix) are available. The main objective of this study is to assess the immunogenicity of ninevalent and bivalent HPV vaccines when administered to 9-10-year-old girls and boys according to 0-6 month schedule.
Gender:
ALL
Ages:
Between 9 years and 10 years
Trial Updated:
01/15/2019
Locations: Équipe de recherche en vaccination, Quebec, Not set
Conditions: HPV Vaccines Immunogenicity and Safety
Register for Updates
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
NCT00224484
Completed
Main goal of this study is to compare the occurrence of serious adverse events (SAEs) between the herpes simplex (gD2-AS04) vaccine group and the Saline control group throughout the study period (up to month 12). The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Gender:
FEMALE
Ages:
Between 10 years and 17 years
Trial Updated:
01/03/2019
Locations: GSK Investigational Site, Birmingham, Alabama +151 locations
Conditions: Herpes Simplex
Register for Updates
Hepatitis B Booster Study in Adolescence
NCT02169674
Completed
This study looks at protection in 10-11 and 15-16 year olds, immunized as infants with Hepatitis B (HB) vaccine to see if they still have residual protection against Hepatitis B disease. Adolescents will be invited to have a blood test and those without a minimal level of protection (antibody titer) will be offered a "test" vaccination to see if they still have capacity to recall an immune response. About one month later they will get another blood test to see if a booster response occurred. A f... Read More
Gender:
ALL
Ages:
Between 10 years and 16 years
Trial Updated:
12/11/2018
Locations: Vaccine Evaluation Center (University of BC at Children's Hospital), Vancouver, British Columbia
Conditions: Hepatitis B
Register for Updates
A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.
NCT02052726
Completed
This study will investigate a clostridium difficile vaccine in healthy adults aged 50 to 85 years, who will each receive 3 doses of vaccine. Subjects will receive their vaccine doses at either months 0, 1, and 3 or days 1, 8, and 30. Subjects will be divided into 2 age groups (50-64 and 65-85 years of age). The study will assess how safe and tolerable the vaccine is, and also look at subjects' immune response to the vaccine.
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
11/30/2018
Locations: Vince & Associates Clinical Research, Inc., Overland Park, Kansas +9 locations
Conditions: Clostridium Difficile
Register for Updates
Zoster Vaccine Response in the Frail Elderly
NCT01328548
Completed
This study is being done to evaluate the zoster vaccine response in the nursing home elderly (80 years or older). As the immune system ages, the response to vaccines is not always as strong as in younger people. Previous zoster vaccine studies have excluded nursing home residents so the vaccine effect in this population is not known. Furthermore, the immune and genetic reasons as to why the vaccine works well in some people but not in others are also unknown. The goal of this study is to evaluat... Read More
Gender:
ALL
Ages:
80 years and above
Trial Updated:
10/25/2018
Locations: Macassa Lodge, Hamilton, Ontario
Conditions: Immune System Diseases
Register for Updates
Live Versus Inactivated Influenza Vaccine Study in Hutterite Children
NCT01653015
Completed
There is uncertainty about whether a live attenuated vaccine (LAIV) offers additional benefit over inactivated trivalent influenza vaccine (TIV) in providing indirect benefit to those who are unvaccinated through herd immunity. The goal of this randomized clinical trial is to determine whether immunizing children in Hutterite colonies with LAIV can provide increased community-wide protection over TIV. Children aged 3 to 15 years in Hutterite colonies from Alberta and Saskatchewan will be randomi... Read More
Gender:
ALL
Ages:
All
Trial Updated:
10/25/2018
Locations: McMaster University, Hamilton, Ontario
Conditions: Influenza
Register for Updates
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster
NCT01827839
Completed
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in subjects' ≥ 50 years of age (YOA) who previously have had Herpes Zoster (HZ). The data collected will be compared with the data from subjects without HZ in other HZ/su trials.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
09/20/2018
Locations: GSK Investigational Site, Coquitlam, British Columbia +3 locations
Conditions: Herpes Zoster
Register for Updates
Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)
NCT00310856
Completed
To assess the immunogenicity of Novartis (formerly Chiron) Meningococcal ACWY conjugate vaccine (MenACWY) when administered as a two-dose schedule at 6 and 12 months of age.
Gender:
ALL
Ages:
Between 6 months and 12 months
Trial Updated:
09/10/2018
Locations: Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario +2 locations
Conditions: Meningococcal Meningitis
Register for Updates
Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life
NCT01214837
Completed
The purpose of this study was to assess immunogenicity of a 3-dose versus 4-dose infant vaccination schedule including kinetics of immune response in the early phases of the series.
Gender:
ALL
Ages:
Between 55 days and 89 days
Trial Updated:
09/10/2018
Locations: Not set, Birmingham, Alabama +39 locations
Conditions: Meningococcal Disease, Meningococcal Meningitis
Register for Updates
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
NCT01196975
Completed
This study is designed to test the immunogenicity and safety of an investigational influenza vaccine, in adults compared to two other influenza vaccines. This study will also evaluate the lot-to-lot consistency of three vaccine lots.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/22/2018
Locations: GSK Investigational Site, Mesa, Arizona +11 locations
Conditions: Influenza
Register for Updates